Inclacumab
Sign in to saveInclacumab (also known as LC-1004-002, RO4905417, and PF-07940370) is an investigational monoclonal antibody originally developed by Roche for cardiovascular disease and later acquired by Global Blood Therapeutics (GBT), which was subsequently acquired by Pfizer in 2022 for $5.4 billion. It is a fully human monoclonal antibody against P-selectin being developed primarily for the treatment of sickle cell disease with vaso-occlusive crises.
In the Vinony graph
Within Vinony's link graph, Inclacumab is referenced by 71 other articles, and connects out to human, World Health Organization and bone.
It is catalogued under topics including Chemical pages without DrugBank identifier, Chemicals that do not have a ChemSpider ID assigned and Drugs not assigned an ATC code.
Its subject is documented across 5 Wikipedia language editions.
Wikidata facts
- Subclass of
- chemical compound
Show 1 more fact
- subject has role
- monoclonal antibody
via Wikidata · CC0
~4 min read
Encyclopedic overview
8 sectionsContents
- Mechanism of action
- Clinical development
- Phase I studies
- Cardiovascular studies
- Sickle cell disease studies
- Safety profile
- Regulatory status
- References
Inclacumab (also known as LC-1004-002, RO4905417, and PF-07940370) is an investigational monoclonal antibody originally developed by Roche for cardiovascular disease and later acquired by Global Blood Therapeutics (GBT), which was subsequently acquired by Pfizer in 2022 for $5.4 billion. It is a fully human monoclonal antibody against P-selectin being developed primarily for the treatment of sickle cell disease with vaso-occlusive crises.
== Mechanism of action == Inclacumab is a recombinant monoclonal antibody against P-selectin, with potential anti-inflammatory, antithrombotic, and antiatherogenic properties. P-selectin works to mediate leukocyte, platelet, and endothelial interactions through the binding of P-selectin to the P-selectin glycoprotein ligand (PSGL)-1 located on the surface of leukocytes.
Excerpted from Wikipedia’s “Inclacumab” article, available under the CC BY-SA 4.0 licence.